The Business of RNAi Therapeutics in 2012.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

31 citing papers in PubMed.

1. Recent advances in understanding of the mechanisms of RNA interference in insects.Insect molecular biology · 2025
   Review
2. The future of siRNA-mediated approaches to treat von Willebrand disease.Expert review of hematology · 2025
   Review
3. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.Frontiers in immunology · 2023
   Review
4. Small RNAs in parasitic nematodes - forms and functions.Parasitology · 2020
   Review
5. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.Cells · 2020
   Review
6. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.Advanced materials (Deerfield Beach, Fla.) · 2019
   Review
7. The current state and future directions of RNAi-based therapeutics.Nature reviews. Drug discovery · 2019
   Review
8. Editorial focus: understanding off-target effects as the key to successful RNAi therapy.Cellular & molecular biology letters · 2019
   Review
9. Ki67 targeted strategies for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
   Review
10. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.Drug delivery and translational research · 2018
    Review
11. Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.Molecular therapy. Nucleic acids · 2017
    Review
12. Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.Molecular therapy. Nucleic acids · 2016
    Article
13. CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs.Cell stem cell · 2016
    Article
14. Technologies for controlled, local delivery of siRNA.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Review
15. A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.Biotechnology advances · 2015
    Review
16. Targeting microRNAs for immunomodulation.Current opinion in pharmacology · 2015
    Review
17. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.Advanced functional materials · 2015
    Article
18. RNA interference. Drugging RNAi.Science (New York, N.Y.) · 2015
    Article
19. IP3 signalling regulates exogenous RNAi in Caenorhabditis elegans.EMBO reports · 2015
    Article
20. Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors.Nucleic acids research · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.